Clinical Trial

A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regimens and been treated with an immunomodulatory imide drug (IMiD), proteasome inhibitor (PI) and an anti-CD38 monoclonal antibody (mAb).
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-08-25; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-11-27
Status change: Active, Not Recruiting → Recruiting 2024-10-24
Status change: Recruiting → Active, Not Recruiting 2024-10-10
Status change: Not Yet Recruiting → Recruiting 2022-07-26
Trial Details
NCT Number NCT05028348
Lead Sponsor European Myeloma Network B.V.
Collaborators: Karyopharm Therapeutics Inc
Conditions Multiple Myeloma
Enrollment 117 participants
Start Date 2022-04-19
Primary Completion 2026-03 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2025-12-04